New studies will compare the effects of common heart medications
Which medication should be used to treat patients with type 2 diabetes, heart failure or chronic kidney disease when there are several medications within the same category? Postdoc Kasper Bonnesen will now investigate this, and he has received DKK 1.2 million for the project from the Danish Diabetes and Endocrine Academy (DDEA).
Treatment with so-called sodium-glucose co-transporter 2 (SGLT2) inhibitors reduces the risk of cardiovascular diseases in patients with diabetes, heart failure or chronic kidney disease. Therefore, these inhibitors are currently the first choice of treatment for these patients. However, no randomised clinical studies have compared the beneficial effects of the different types of SGLT2 inhibitors, so Kasper Bonnesen will now do this with a research grant of DKK 1.2 million from the DDEA.
Using data from national Danish registers on prescriptions, hospital diagnoses and laboratory tests, Kasper Bonnesen will conduct three population-based cohort studies. The purpose is to compare the effects of the SGLT2 inhibitors empagliflozin, dapagliflozin, canagliflozin and ertougliflozin on reducing the risk of blood clots in the heart or the brain, heart failure and death for these patient groups.
"The results of the studies will provide clinicians with important knowledge about which specific medications they should prescribe to the patient groups. This could potentially improve how clinicians prescribe medications and not least patient prognosis," says Kasper Bonnesen, who is affiliated with the Department of Clinical Epidemiology.
The coverage is based on press material from the Danish Diabetes and Endocrine Academy.
Contact
MD, PhD and Postdoc Kasper Bonnesen
Aarhus University, Department of Clinical Medicine - Department of Clinical Epidemiology
Telephone: +45 87 16 78 95
Email: bonnesen@clin.au.dk